ENZAMET trial results to be presented at ASCO

The results of the 1,125-patient, randomized, double-blind ENZAMET trial are to be reported in a late-breaking abstract at the upcoming annual meeting of the American Society for Clinical Oncology (ASCO) in Chicago. … READ MORE …

NOW AVAILABLE … the new PCa Social Network PLUS app

Back in February this year we had told you about the development of a new type of social network that would (a) allow men to share information about their prostate cancer with each other and (b) collect that data to evaluate whether such networking improved patients’ quality of life. … READ MORE …

Spontaneous remission in low-risk forms of prostate cancer

The issue of spontaneous remission of low-risk forms of prostate cancer came up yesterday during a meeting of Prostate Cancer International’s Active Surveillance Virtual Support Group (ASVSG). … READ MORE …

What did we learn at the AUA this year?

The annual meeting of the American Urological Association (AUA) is one at which a great deal of information is exchanged, but a lot of that information is of limited utility to patients. … READ MORE …

No association between alcohol consumption and lethal prostate cancer

A newly published article in the Journal of Clinical Oncology has again confirmed that there seems to be no really meaningful association between moderate alcohol consumption and risk for lethal prostate cancer. … READ MORE …

J&J to seek approval of apalutamide in treatment of mCSPC

According to a media release issued yesterday by Johnson & Johnson, its Janssen Pharmaceuticals division has just submitted an application to the U.S. Food and Drug Administration for the approval of apalutamide (Eleada) in the treatment of men with metastatic, castration-sensitive prostate cancer (mCSPC). … READ MORE …

Is there an “oligometastatic state” for prostate cancer?

The concept of an “oligometastatic state” is based on the idea that there is an “early advanced” stage of cancer during which metastases are few in number and are in some way different from metastases that develop later. … READ MORE …